



Resource: ART Drug-Drug Interactions

April 2023

| Table 37: Hormonal Contraceptives (also see drug package inserts) | | |
|---|--|--|
| → Combined oral contraceptives, including ethinyl estradiol, norethindrone, and levonorgestrel | | |
| Class or Drug | Mechanism of Action | Clinical Comments |
| <ul style="list-style-type: none"> • NRTIs • Dolutegravir (DTG) • Bictegravir (BIC) • Cabotegravir (CAB) • Raltegravir (RAL) • Doravirine (DOR) | No significant drug interactions reported. | No dose adjustments are necessary. |
| Elvitegravir (EVG), boosted | Drospirenone: Concomitant use may cause hyperkalemia. | <ul style="list-style-type: none"> • Ethinyl estradiol, norgestimate and metabolites; norethindrone: Weigh risks and benefits; consider alternative contraceptive methods. • Drospirenone: Monitor for hyperkalemia; consider alternative contraceptive methods or alternative ARV. • Etonogestrel: No data available; consider alternative or additional contraceptive method or alternative ARV. |
| All PIs | Combination has not been studied. | Etonogestrel: No data available. Consider alternative or additional contraceptive methods or alternative ARV. |
| Atazanavir (ATV), unboosted | Complex drug interaction potential has been described. | <ul style="list-style-type: none"> • Ethinyl estradiol: Do not exceed 30 mcg (no data available on doses lower than 25 mcg). • Norethindrone: Do not exceed 30 mcg (no data available on oral contraceptives with <25 mcg of ethinyl estradiol or progestins other than norethindrone or norgestimate). |
| Atazanavir (ATV), boosted | <ul style="list-style-type: none"> • Complex drug interaction potential has been described. • Drospirenone: Concomitant use may cause hyperkalemia. | <ul style="list-style-type: none"> • Ethinyl estradiol; norgestimate and metabolites: Dose with at least 35 mcg (no data available on other progestins). • Drospirenone: Do not coadminister. |
| Darunavir (DRV)/ritonavir (RTV) | Combination appears to decrease oral norethindrone concentrations. | Norethindrone: Consider alternative or additional contraceptive methods or alternative ARV. |
| Darunavir (DRV)/cobicistat (COBI) | Combination has not been studied, but since COBI does not induce glucuronidation, it is expected to increase norethindrone concentrations. | Norethindrone: Consider alternative or additional contraceptive methods or alternative ARV. |
| Other boosted PIs | Drospirenone: Use with other boosted PIs may cause hyperkalemia. | <ul style="list-style-type: none"> • Ethinyl estradiol: Consider alternative or additional contraceptive methods or alternative ARV. • Drospirenone: Monitor for hyperkalemia; consider alternative contraceptive or alternative ARV. |

| Table 37: Hormonal Contraceptives (also see drug package inserts) | | |
|--|--|--|
| → Combined oral contraceptives, including ethinyl estradiol, norethindrone, and levonorgestrel | | |
| Class or Drug | Mechanism of Action | Clinical Comments |
| Efavirenz (EFV) | <ul style="list-style-type: none"> • Levonorgestrel/norgestimate, levonorgestrel: EFV may induce CYP3A, the enzyme that is primarily responsible for metabolism of levonorgestrel. • EFV decreases concentrations of combined progestins. | <ul style="list-style-type: none"> • Levonorgestrel/norgestimate, levonorgestrel: Levonorgestrel or norgestimate effectiveness may be decreased. • Ethinyl estradiol; norgestimate and metabolites: Use alternative or additional contraceptive methods; unintended pregnancies have been reported in individuals using levonorgestrel implants. • Norethindrone, drospirenone, etonogestrel: Consider alternative or additional contraceptive methods or alternative ARV. • Ulipristal: Monitor closely for reduced efficacy. |
| Etravirine (ETR) | Information is based on what is known with EFV drug interactions. | <ul style="list-style-type: none"> • Etonogestrel: No data available; consider alternative or additional contraceptive methods or alternative ARV. • Ulipristal: Monitor closely for reduced efficacy. |
| Fostemsavir (FTR) | <ul style="list-style-type: none"> • Ethinyl estradiol: Increased ethinyl estradiol levels are expected. • Norethindrone: No interactions are expected. | Ethinyl estradiol: Daily dose should not exceed 30 mcg. Caution is advised, particularly in patients with additional risk factors for thromboembolic events. |
| Abbreviations: ARV, antiretroviral; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. | | |